Literature DB >> 15647750

Effects of acute tryptophan depletion on negative symptoms and smoking topography in nicotine-dependent schizophrenics and nonpsychiatric controls.

Brian Hitsman1, Bonnie Spring, William Wolf, Regina Pingitore, John W Crayton, Donald Hedeker.   

Abstract

We studied the effect of acute tryptophan depletion (ATD), which transiently reduces brain serotonin, on negative symptoms and cigarette smoking topography in schizophrenic smokers. Nicotine-dependent schizophrenics (n=11) and nonpsychiatric controls (n=8) were examined after ingesting comparable mixtures that do and do not deplete plasma tryptophan. Tryptophan-depleting and placebo mixtures were administered double-blind and in counterbalanced order. Conditions were separated by a 1-week interval. Psychopathologic symptoms (negative symptoms, depression) and smoking topography (time to first puff, number of puffs per cigarette, puff duration, interpuff interval, cigarette duration, and percentage of cigarette smoked) were measured before ingestion and again beginning 5 h after each mixture, corresponding to the time of maximal tryptophan depletion. Analyses were conducted using repeated measures analyses of variance (psychopathologic symptoms) and analyses of covariance (smoking topography) controlling for cigarette length. We found that ATD influenced smoking topography in both schizophrenics and nonpsychiatric controls in a manner suggestive of increased desire to smoke. Schizophrenics exhibited increased puff duration and decreased cigarette duration. Controls displayed increased puff duration. ATD did not produce changes in negative symptoms or depression. Compromising brain serotonin via ATD appears to intensify smoking behavior in nicotine-dependent individuals directly, rather than indirectly through changes in either mood or psychopathologic symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15647750     DOI: 10.1038/sj.npp.1300651

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  7 in total

1.  Genetic variation in the serotonin pathway and smoking cessation with nicotine replacement therapy: new data from the Patch in Practice trial and pooled analyses.

Authors:  Sean P David; Elaine C Johnstone; Michael F G Murphy; Paul Aveyard; Boliang Guo; Caryn Lerman; Marcus R Munafò
Journal:  Drug Alcohol Depend       Date:  2008-06-17       Impact factor: 4.492

Review 2.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

3.  Acute psychomotor, subjective and physiological responses to smoking in depressed outpatient smokers and matched controls.

Authors:  Debra Malpass; Suzanne Higgs
Journal:  Psychopharmacology (Berl)       Date:  2006-11-30       Impact factor: 4.530

4.  Socio-demographic and clinical characteristics of heavy and non-heavy smokers among schizophrenia inpatients in a Chinese Han population.

Authors:  Xiang Yang Zhang; Da Chun Chen; Yun Long Tan; Mei Hong Xiu; Jingyi Cui; Li Hui; Fu De Yang; Thomas R Kosten
Journal:  Psychopharmacology (Berl)       Date:  2013-08-21       Impact factor: 4.530

5.  Smoking topography and outcome expectancies among individuals with schizotypy.

Authors:  Diana W Stewart; Christine Vinci; Claire E Adams; Alex S Cohen; Amy L Copeland
Journal:  Psychiatry Res       Date:  2012-12-20       Impact factor: 3.222

6.  Clinical characteristics of heavy and non-heavy smokers with schizophrenia.

Authors:  Heidi J Wehring; Fang Liu; Robert P McMahon; Kristen M Mackowick; Raymond C Love; Lisa Dixon; Deanna L Kelly
Journal:  Schizophr Res       Date:  2012-05-10       Impact factor: 4.939

7.  Effect of tryptophan depletion on the attentional salience of smoking cues.

Authors:  Brian Hitsman; Bonnie Spring; Regina Pingitore; Marcus Munafò; Donald Hedeker
Journal:  Psychopharmacology (Berl)       Date:  2007-02-14       Impact factor: 4.415

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.